Kunihiko Itoh

10PUBLICATIONS
23CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEpidemiological modellingMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 19, 2026
Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer.

|Aug 28, 2026
Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study.

|Jun 01, 2026
Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study.

|Mar 06, 2026
NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts.

Hisanaga Nomura, Takaya Suzuki, Takashi Kojima

|Apr 29, 2024
Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).

Masahiro Hatori, Daiki Tsuji, Kenichi Suzuki

|Jan 03, 2024
Changes in estimated glomerular filtration rate in patients administered proton pump inhibitors: a single-center cohort study.

Takuma Murofushi, Tatsuya Yagi, Daiki Tsuji

Pageof 2

Frequent Collaborators

6 joint publications

Daiki Tsuji

4 joint publications

Keita Hirai

4 joint publications

Masahiro Hatori

4 joint publications

Takashi Yokokawa